Pathophysiology of the pleura

Respiration

Volumn 75, Issue 2, 2008, Pages 121-133

  Jantz, Michael A ^a   Antony, Veena B ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Empyema; Malignant pleural effusion; Mesothelium; Pleura; Pleural fibrosis; Pleurodesis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CHEMOKINE; CYTOKINE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

CELL POPULATION; DEFENSE MECHANISM; FIBROBLAST; GRANULOMATOSIS; HUMAN; INFECTION; INFLAMMATION; LYMPHOCYTE; MESOTHELIUM; NEUTROPHIL; PATHOPHYSIOLOGY; PLEURA; PLEURA CAVITY; PLEURA EFFUSION; PLEURAL FIBROSIS; PLEURODESIS; PRIORITY JOURNAL; REVIEW;

CYTOKINES; EPITHELIUM; FIBROSIS; HUMANS; PLEURA; PLEURAL DISEASES; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS;

EID: 40549146547     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113629     Document Type: Review

References (95)

1. Wang N: Mesothelial cells in situ; in Chretien J, Bignon J, Hirsch A (eds): The Pleura in Health and Disease. New York, Dekker, 1985, pp 23-42.
2. Medzhitov R, Janeway CA Jr: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
3. Ohtsuka A, Yamana S, Murakami T: Localization of membrane-associated sialomucin on the free surface of mesothelial cells of the pleura, pericardium, and peritoneum. Histochem Cell Biol 1997;107:441-447.
4. Sassetti C, Van Zante A, Rosen SD: Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem 2000;275:9001-9010.
5. Sharma RK, Mohammed KA, Nasreen N, Hardwick J, Van Horn RD, Ramirez-Icaza C, Antony VB: Defensive role of pleural mesothelial cell sialomucins in tumor metastasis. Chest 2003;124:682-687.
6. Owens MW, Milligan SA, Grisham MB: Nitric oxide synthesis by rat pleural mesothelial cells: induction by growth factors and lipopolysaccharide. Exp Lung Res 1995;21: 731-742.
7. Owens MW, Grisham MB: Nitric oxide synthesis by rat pleural mesothelial cells: induction by cytokines and lipopolysaccharide. Am J Physiol 1993;265:L110-L116.
8. Heine H, Ulmer AJ: Recognition of bacterial products by toll-like receptors. Chem Immunol Allergy 2005;86:99-119.
9. Delves PJ, Roitt IM: The immune system: second of two parts. N Engl J Med 2000;343: 108-117.
10. Delves PJ, Roitt IM: The immune system: first of two parts. N Engl J Med 2000;343: 37-49.
11. Mohammed KA, Nasreen N, Ward MJ, Antony VB: Induction of acute pleural inflammation by Staphylococcus aureus: CD4+ T cells play a critical role in experimental empyema. J Infect Dis 2000;181:1693-1699.
12. Antony VB: Immunological mechanisms in pleural disease. Eur Respir J 2003;21:539-544.
13. Jonjic N, Peri G, Bernasconi S, Sciacca F, Colotta F, Pelicci P, Lanfrancone L, Mantovani A: Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 1992;176:1165-1174.
14. Antony VB, Hott JW, Kunkel SL, Godbey SW, Burdick MD, Strieter RM: Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am J Respir Cell Mol Biol 1995; 12:581-588.
15. Janeway CR, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002;20: 197-216.
16. Tosi MF: Innate immune responses to infection. J Allergy Clin Immunol 2005;116:241-249.
17. Schnare M, Rollinghoff M, Qureshi S: Toll-like receptors: sentinels of host defence against bacterial infection. Int Arch Allergy Immunol 2006;139:75-85.
18. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J: Human beta-defensins. Cell Mol Life Sci 2006;63:1294-1313.
19. Niyonsaba F, Ogawa H, Nagaoka I: Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004;111:273-281.
20. Ashitani J, Mukae H, Nakazato M, Taniguchi H, Ogawa K, Kohno S, Matsukura S: Elevated pleural fluid levels of defensins in patients with empyema. Chest 1998;113: 788-794.
21. Strieter RM, Koch AE, Antony VB, Fick RB Jr, Standiford TJ, Kunkel SL: The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994;123:183-197.
22. Broaddus VC, Boylan AM, Hoeffel JM, Kim KJ, Sadick M, Chuntharapai A, Hebert CA: Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin-induced pleurisy. J Immunol 1994;152:2960-2967.
23. Antony VB, Sahn SA, Antony AC, Repine JE: Bacillus Calmette-Guerin- stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 1985;76:1514-1521.
24. Ellner JJ, Barnes PF, Wallis RS, Modlin RL: The immunology of tuberculous pleurisy. Semin Respir Infect 1988;3:335-342.
25. Malech H: Phagocytic cells: egress from marrow and diapedesis; in Gallin JG, Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates. New York, Raven, 1988, pp 297-308.
26. Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM: Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996;98:2050-2059.
27. Nasreen N, Hartman D, Mohammed K, Antony V: Talc induces pleural mesothelial cell expression of proinflammatory cytokines and intracellular adhesion molecule (ICAM-1). Am J Respir Crit Care Med 1998;158:971-978.
28. Spitznagel J: Nonoxidative antimicrobial reactions of leukocytes. Contemp Top Immunobiol 1984;14:283-343.
29. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427-1435.
30. Cox G, Gauldie J, Jordana M: Bronchial epithelial cell-derived cytokines (G-CSF and GM-CSF) promote the survival of peripheral blood neutrophils in vitro. Am J Respir Cell Mol Biol 1992;7:507-513.
31. Nasreen N, Mohammed KA, Sanders KL, Hardwick J, Van Horn RD, Loghmani F, Lundin MC, Antony VB: Differential expression of C-phos, C-June, and apoptosis in pleural mesothelial cells exposed to Staph. aureus. Am J Respir Crit Care Med 2001;163: A772.
32. Payne CM, Glasser L, Tischler ME, Wyckoff D, Cromey D, Fiederlein R, Bohnert O: Programmed cell death of the normal human neutrophil: an in vitro model of senescence. Microsc Res Tech 1994;28:327-344.
33. Sahn SA: State of the art: the pleura. Am Rev Respir Dis 1988;138:184-234.
34. Mantovani A, Garlanda C: Novel pathways for negative regulation of inflammatory cytokines centered on receptor expression. Dev Biol Stand 1999;97:97-104.
35. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA, Hayakawa Y: Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501-510.
36. Loghmani F, Mohammed KA, Nasreen N, Van Horn RD, Hardwick JA, Sanders KL, Antony VB: Inflammatory cytokines mediate C-C (monocyte chemotactic protein 1) and C-X-C (interleukin 8) chemokine expression in human pleural fibroblasts. Inflammation 2002;26:73-82.
37. Hott JW, Godbey SW, Antony VB: Mesothelial cell modulation of pleural repair: thrombin stimulated mesothelial cells release prostaglandin E2. Prostaglandins Leukot Essent Fatty Acids 1994;51:329-335.
38. Rennard S, Jaurand M, Bignon J, Ferrans V, Crystal R: Connective tissue matrix of the pleura; in Chretien J, Bignon J, Hirsch A (eds): The Pleura in Health and Disease. New York, Dekker, 1985, pp 69-85.
39. Antony VB: Pathogenesis of malignant pleural effusions and talc pleurodesis. Pneumologie 1999;53:493-498.
40. Ponta H: The CD44 protein family. Int J Biochem Cell Biol 1998;30:299-305.
41. Bourguignon LY, Lokeshwar VB, Chen X, Kerrick WG: Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J Immunol 1993;151:6634-6644.
42. Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, Loghmani F, Antony VB: Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res 2002;13: 71-78.
43. Sriram PS, Mohammed KA, Nasreen N, Hardwick J, Van Horn R, Sanders K, Antony VB: Adherence of ovarian cancer cells induces pleural mesothelial cell (PMC) permeability. Oncol Res 2002;13:79-85.
44. Nasreen N, Mohammed KA, Antony VB: Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006;107:2425-2435.
45. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10: 5145-5150.
46. Kinch MS, Moore MB, Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9:613-618.
47. Easty DJ, Herlyn M, Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995;60:129-136.
48. Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z: Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res 2005;25:2943-2950.
49. Nasreen N, Mohammed KA, Lai Y, Antony VB: Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett 2007;258: 215-222.
50. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
51. Nasreen N, Mohammed KA, Sanders K, Hardwick J, Van Horn RD, Sriram PS, Ramirez-Icaza C, Hage C, Antony VB: Pleural mesothelial cell (PMC) defense mechanisms against malignancy. Oncol Res 2003; 14:155-161.
52. Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, Loddenkemper R, Antony VB: Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 2007;29:761-769.
53. Becker PM, Alcasabas A, Yu AY, Semenza GL, Bunton TE: Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol 2000;22:272-279.
54. Thickett DR, Armstrong L, Millar AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707-710.
55. Ishimoto O, Saijo Y, Narumi K, Kimura Y, Ebina M, Matsubara N, Asou N, Nakai Y, Nukiwa T: High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 2002;63:70-75.
56. Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE, Antony VB: Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001;281:L119-L125.
57. Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R, Muller WA, Hicklin DJ, Bohlen P, Dejana E: Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 2001;97:1679-1684.
58. Blankesteijn WM, van Gijn ME, Essers-Janssen YP, Daemen MJ, Smits JF: Beta-catenin, an inducer of uncontrolled cell proliferation and migration in malignancies, is localized in the cytoplasm of vascular endothelium during neovascularization after myocardial infarction. Am J Pathol 2000; 157:877-883.
59. Dejana E: Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1996;98:1949-1953.
60. Lee YC, Lane KB: The many faces of transforming growth factor-beta in pleural diseases. Curr Opin Pulm Med 2001;7:173-179.
61. Antony VB, Sahn SA, Mossman B, Gail DB, Kalica A: Pleural cell biology in health and disease. Am Rev Respir Dis 1992;145:1236-1239.
62. Harvey W, Amlot PL: Collagen production by human mesothelial cells in vitro. J Pathol 1993;19:445-452.
63. Ma C, Tarnuzzer RW, Chegini N: Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta 1. Wound Repair Regen 1999;7:477-485.
64. Idell S, Zweib C, Kumar A, Koenig KB, Johnson AR: Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992;7:414-426.
65. Falk P, Ma C, Chegini N, Holmdahl L: Differential regulation of mesothelial cell fibrinolysis by transforming growth factor beta 1. Scand J Clin Lab Invest 2000;60:439-447.
66. Sasse SA, Jadus MR, Kukes GD: Pleural fluid transforming growth factor-β1 correlates with pleural fibrosis in experimental empyema. Am J Respir Crit Care Med 2003;168: 700-705.
67. Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T, Higashino K: Local production and localization of transforming growth factor-beta in tuberculous pleurisy. Clin Exp Immunol 1993;92:32-38.
68. Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Begin R, Rom WN: Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 1997;105(suppl 5):1197-1203.
69. Light RW, Cheng DS, Lee YCG, Rogers J, Davidson J, Lane KB: A single intrapleural injection of transforming growth factor beta-2 produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000;162:98-104.
70. 2) produces effective pleurodesis in sheep with no systemic complications. Thorax 2000;55: 1058-1062.
71. Mutsaers SE, McAnulty RJ, Laurent GJ, Versnel MA, Whitaker D, Papadimitriou JM: Cytokine regulation of mesothelial cell proliferation in vitro. Eur J Cell Biol 1997;72: 24-29.
72. Bikfalvi A, Klein S, Pintucci G, Rifkin DB: Biologic roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
73. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988;130:393-400.
74. Friesel RE, Maciag T: Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995;9:919-925.
75. Abramov Y, Anteby SO, Fasouliotis SJ, Barak V: Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. Am J Obstet Gynecol 2001;184:354-355.
76. Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A: Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001;18:1093-1098.
77. Antony VB, Nasreen N, Mohammed KA, Sriram PS, Frank W, Schoenfeld N, Loddenkemper R: Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest 2004;126:1522-1528.
78. Owens MW, Milligan SA: Growth factor modulation of rat pleural mesothelial cell mitogenesis and collagen synthesis. Effects of epidermal growth factor and platelet-derived factor. Inflammation 1994;18:77-87.
79. Waters CM, Chang JY, Glucksberg MR, DePaola N, Grotberg JB: Mechanical forces alter growth factor release by pleural mesothelial cells. Am J Physiol 1997;272:L552-L557.
80. Safi A, Sadmi M, Martinet N, Menard O, Vaillant P, Gallati H, Hosang M, Martinet Y: Presence of elevated levels of platelet-derived growth factor (PDGF) in lung adenocarcinoma pleural effusions. Chest 1992;102:204-207.
81. Heldin P, Asplund T, Ytterberg D, Thelin S, Laurent TC: Characterization of the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-derived growth factor in human mesothelial cells. Biochem J 1992;283:165-170.
82. Adamson IYR, Prieditis H, Young L: Lung mesothelial cell and fibroblast responses to pleural and alveolar macrophage supernatants and to lavage fluids from crocidolite-exposed rats. Am J Respir Cell Mol Biol 1997; 16:650-656.
83. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF: Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol 1989;109:429-440.
84. Idell S: Pleural fibrosis; in Light RW, Lee YCG (eds): Textbook of Pleural Diseases. London, Arnold, 2003, pp 96-108.
85. Mutsaers SE, Prele CM, Brody AR, Idell S: Pathogenesis of pleural fibrosis. Respirology 2004;9:428-440.
86. Idell S, Girard W, Koenig KB, McLarty J, Fair DS: Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991;144:187-194.
87. McGee M, Rothberger H: Tissue factor in bronchoalveolar lavage fluids. Evidence for an alveolar macrophage source. Am Rev Respir Dis 1985;131:331-336.
88. Idell S, Zwieb C, Boggaram J, Holiday D, Johnson AR, Raghu G: Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-β and TNF-α. Am J Physiol 1992;263:L487-L494.
89. Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S: Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells and lung fibroblasts. Eur Respir J 2000;15:1069-1078.
90. Vassalli JD, Sappino AP, Berlin D: The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-1072.
91. Shetty S, Kumar A, Johnson AR, Idell S: Regulation of mesothelial cell mitogenesis by antisense oligonucleotides for the urokinase receptor. Antisense Res Dev 1995;5:307-314.
92. Sitrin RG, Todd RF 3rd, Albrecht E, Gyetko MR: The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996;97:1942-1951.
93. Shetty S, Idell S: A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am J Physiol 1998;274: L871-L872.
94. Chapman HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-724.
95. Shetty S, Kumar A, Johnson AR, Pueblitz S, Holiday D, Raghu G, Idell S: Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 1996;15:78-87.